LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

Adam Ceroi, David Masson, Anne Roggy, Christophe Roumier, Cécile Chagué, Thierry Gauthier, Laure Philippe, Baptiste Lamarthée, Fanny Angelot-Delettre, Francis Bonnefoy, Sylvain Perruche, Sabeha Bichle, Claude Preudhomme, Elisabeth Macintyre, Laurent Lagrost, Francine Garnache-Ottou and Philippe Saas

1Unité 1098, INSERM, Besançon, France; 2Université Bourgogne Franche-Comté, Unité Mixte de Recherche 1098, Besançon, France; 3Etablissement Français du Sang Bourgogne Franche-Comté, Besançon, France; 4Laboratoires d’Excellence (LabEx) Lipoprotéines et Santé: Prévention et Traitement des Maladies Inflammatoires et du Cancer (LipSTIC), Besançon/Dijon, France; 5Faculté de Médecine, Université Bourgogne Franche-Comté, INSERM Unité 866, Dijon, France; 6Laboratoire d’Hématologie, Centre de Biologie Pathologie, Institut de Recherches sur le Cancer de Lille, Centre Hospitalier Régional Universitaire de Lille, INSERM Unité 837, Lille, France; and 7Laboratoire d’Onco-Hématologie, Hôpital Necker-Enfants Malades, Assistance Publique–Hôpitaux de Paris, Faculté de Médecine Descartes, Université Sorbonne Paris Cité, INSERM Unité 1151, Paris, France

Key Points

- LXR activation inhibits BPDCN cell survival through the increase of cholesterol efflux, the inhibition of NF-κB, and IL-3 signaling.
- Treatment with LXR agonists can be proposed as a new therapeutic approach for BPDCN.

Blastic plasmacytoid dendritic cell (PDC) neoplasm (BPDCN) is an aggressive hematological malignancy with a poor prognosis that derives from PDCs. No consensus for optimal treatment modalities is available today and the full characterization of this leukemia is still emerging. We identified here a BPDCN-specific transcriptomic profile when compared with those of acute myeloid leukemia and T-acute lymphoblastic leukemia, as well as the transcriptomic signature of primary PDCs. This BPDCN gene signature identified a dysregulation of genes involved in cholesterol homeostasis, some of them being liver X receptor (LXR) target genes. LXR agonist treatment of primary BPDCN cells and BPDCN cell lines restored LXR target gene expression and increased cholesterol efflux via the upregulation of adenosine triphosphate–binding cassette (ABC) transporters, ABCA1 and ABCG1. LXR agonist treatment was responsible for limiting BPDCN cell proliferation and inducing intrinsic apoptotic cell death. LXR activation in BPDCN cells was shown to interfere with 3 signaling pathways associated with leukemic cell survival, namely: NF-κB activation, as well as Akt and STAT5 phosphorylation in response to the BPDCN growth/survival factor interleukin-3. These effects were increased by the stimulation of cholesterol efflux through a lipid acceptor, the apolipoprotein A1. In vivo experiments using a mouse model of BPDCN cell xenograft revealed a decrease of leukemic cell infiltration and BPDCN-induced cytopenia associated with increased survival after LXR agonist treatment. This demonstrates that cholesterol homeostasis is modified in BPDCN and can be normalized by treatment with LXR agonists which can be proposed as a new therapeutic approach. (Blood. 2016;128(23):2694-2707)

Introduction

Blastic plasmacytoid dendritic cell (PDC) neoplasm (BPDCN) is a rare aggressive malignancy derived from PDCs. This disease is characterized by a heterogeneous presentation at diagnosis (from a disease limited to the skin to a leukemic syndrome with cytopenia and bone marrow involvement), clinical heterogeneity, and manifestations easily changing during disease progression. Currently, there is no consensus regarding the optimal treatment modality. Most BPDCN patients have a very aggressive clinical course with limited median overall survival. It has been recently proposed that the frequent relapse after treatment and the poor prognosis can be related to the fact that the involvement of the central nervous system (CNS) is frequently undetected. Recently, BPDCN was classified by the World Health Organization (WHO) as a distinct entity in the group of “acute myeloid leukemia (AML) and related precursor neoplasms.” Extensive characterization of this malignancy is still limited and diagnosis overlap may exist with immature AML, monoblastic and undifferentiated leukemia. Thus, a better understanding of this leukemia and new therapeutic approaches are urgently needed.

Previous studies have identified a cholesterol metabolism dysregulation in different malignant cells leading to intracellular cholesterol accumulation. Cellular cholesterol content results from cholesterol uptake and biosynthesis through the mevalonate pathway, while its...
Figure 1. A BPDCN-specific transcriptomic signature with a dysregulation of genes involved in cholesterol homeostasis allows the clustering of BPDCN samples. 
(A) A schematic representation of cellular cholesterol homeostasis. Mechanisms of cholesterol synthesis and uptake (green boxes) and efflux (blue box) maintain cellular cholesterol homeostasis. The LXR pathway is involved in the regulation of cholesterol homeostasis by inhibiting cholesterol uptake/entry (through the decreased expression of low-density lipoprotein (LDL) and/or very-low-density lipoprotein (VLDL) receptors, LDLR and VLDLR, respectively) and by stimulating cholesterol efflux (through ABC transporters, ABCA1 and ABCG1). This LXR pathway is activated by intermediates from the mevalonate pathway (i.e., the cholesterol biosynthesis). Cholesterol efflux also requires cholesterol acceptors, APOA1/APOE, and HDL2/3 to form mature HDL. These cholesterol acceptors can be provided by the cell itself or represent circulating...
elimination is mediated by cholesterol efflux (Figure 1A). Cholesterol uptake involves plasma lipoproteins (mainly LDL and VLDL) after interactions with their specific receptors, LDLR and VLDLR, respectively. Cholesterol efflux implicates mainly adenosine triphosphate–binding cassettes (ABCs) A1 and G1 (ABCA1 and ABCG1, respectively) in association with extracellular cholesterol acceptors, including: apolipoprotein A1/E (APOA1 and APOE, respectively) or lipoprotein particles (eg, nascent high-density lipoprotein [HDL] or HDL2).8

Leukemic cells (AML and chronic myeloid leukemia) have been shown to increase LDLR expression,6 decrease LDLR degradation,7 and stimulate cholesterol biosynthesis resulting in cholesterol accumulation.8 Cholesterol regulates critical cellular functions, including plasma membrane formation, fluidity, and permeability.9 These latter functions are implicated in survival signaling pathway activation (eg, Akt)10 and proliferation.11,12 For instance, stimulation of cholesterol efflux inhibits interleukin-3 (IL-3)-induced hematopoietic progenitor cell proliferation.13,14 Interestingly, BPDCN cell lines (CAL-1 and GEN2.2).29,30 Two established BPDCN cell lines (CAL-1 and GEN2.2),29,30 primary BPDCN cells isolated from a patient and expanded in NOD-SCID IL2Rγc-deficient (NSG) mice (The Jackson Laboratory, Sacramento, CA) (referred to hereafter as BES1), as well as 11 BPDCN samples with different BPDCN infiltration (supplemental Table 1, available on the Blood Web site) from newly diagnosed patients were used for in vitro assays. Culture of BPDCN cells and isolation of primary BPDCN samples are described in supplemental Methods.

Methods

BPDCN collection

Twenty-three BPDCN samples were obtained at diagnosis (sample collection authorization number DC-2008-713). BPDCN was diagnosed based on histopathology and immunostaining of cutaneous lesions, blood, or bone marrow samples, as described.26-28 This study was approved by our local ethics committee (Comité de Protection des Personnes [CPP] Est II, Besançon, France).

Cell lines and culture

Two established BPDCN cell lines (CAL-1 and GEN2.2),29,30 primary BPDCN cells isolated from a patient and expanded in NOD-SCID IL2Rγc-deficient (NSG) mice (The Jackson Laboratory, Sacramento, CA) (referred to hereafter as BES1), as well as 11 BPDCN samples with different BPDCN infiltration (supplemental Table 1, available on the Blood Web site) from newly diagnosed patients were used for in vitro assays. Culture of BPDCN cells and isolation of primary BPDCN samples are described in supplemental Methods.

Transcriptomic analysis

The following samples were submitted to transcriptomic analysis using the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA):

- 12 BPDCN samples,
- 65 AML samples (including different French-American-British subtypes: 25 M0, 11 M1, 10 M2, 1 M3, 11 M4, 6 M5, and 1 M6) (Unité 837, Institut de Recherches sur le Cancer de Lille [IRCL], Lille, France),
- 35 T-ALL samples (Unité 1151, Assistance Publique–Hôpitaux de Paris [AP-HP], Hôpital Necker-Enfants Malades, Paris, France) (available at https://www.dropbox.com/sh/v21hg015hf515gw/AAC63OgjzcXXqTM- myca55yVca?l=0), and
- 5 primary PDCs (available on the Gene Expression Omnibus [GEO] database, under recording numbers: GSM705329, GSM705330, GSM705331, GSM705332, GSM705333).

Data were analyzed using dChip software (http://www.softpedia.com/get/Science-CAD/dChip.shtml) based on the expression of cholesterol homeostasis and LXR-related genes (LXRA, LXRB, ABCA1, ABCG1, APOE, SREBF1, FASN, LDLR, and VLDLR) plus the NFκB1 gene.

Quantitative RT-PCR analysis

Transcription of LXR target genes (ABCA1, ABCG1) and genes coding proteins involved in the intrinsic apoptosis (BCL2, BAK1, BAX) was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR), as described.25 Details are given in supplemental Methods.

Cholesterol efflux assay

CAL-1 cells were used to assess cholesterol efflux, as described in supplemental Methods and in Ishibashi et al.31
Figure 2. LXR activation restores cholesterol homeostasis-related gene expression and induces cholesterol efflux from BPDCN. (A) BPDCN cell lines (CAL-1, GEN2.2) and blood samples from 4 patients diagnosed with BPDCN (LPDC #4, #7, #8, #10) were treated with 1 µM LXR agonists, T0901317 (T09) or GW3965 (GW), for 24 hours. ABCA1 and ABCG1 mRNA levels were determined by qRT-PCR in CAL-1 (n = 8), GEN2.2 (n = 5), and in blood samples containing >75% of leukemic PDCs (n = 4). Levels of mRNA were normalized to those of GAPDH for each sample and then expressed as fold change relative to the average value for vehicle-treated cells (*P < .05,
Flow cytometry

Cytotoxic effects of LXR agonists were evaluated by staining with Annexin V (AnxV) and 7-amino-actinomycin D (7AAD) (fluorescin isothiocyanate–conjugated AnxV/7AAD, BD Biosciences, Le Pont de Claix, France) or caspase-9 activation (CaspGLOW Fluorescein Active Caspase Staining kit; eBioscience), according to the manufacturer’s instructions. Proliferation was assessed on CAL-1 cells after labeling with the cell proliferation dye, eFluor 450 (eBioscience SA, Paris, France). BDPNC gating was performed using antibodies against CD123, CD131, and CD304 (supplemental Table 3). Cell cycle analysis was performed after cell fixation in ethanol 70% (overnight, 4°C), and by propidium iodide staining in a solution containing RNase (overnight, 4°C). Cell fluorescence was evaluated using a CANTO II cytomter (BD Biosciences, San Jose, CA) and DIVA 6.2 software (BD Biosciences), except for cell cycle analysis where a FC500 cytomter with CXP and WinCycle softwares (Beckman Coulter Immunotech, Miami, FL) were used.

Immunoblotting

Whole-cell protein fraction was obtained by cell lysis in Laemmli buffer (supplemental Methods). Nuclear and cytosolic fractions were isolated by centrifugation while nuclei were lysed in Laemmli buffer. Proteins were separated by electrophoresis on 8.5% or 12% sodium dodecyl sulfate–polyacrylamide gels and transferred to polyvinylidene difluoro membranes (GE Healthcare). Blots were then saturated with 5% milk before incubation with specific antibodies (supplemental Table 3). Blotted proteins were detected and quantified on a bioimunessence imager and BIO-1D advanced software (Vilber-Lourmat, Marne-la-Vallée, France) after blots were incubated with a horseradish peroxidase–conjugated appropriate secondary antibody. Details on blot saturation and quantification are given in supplemental Methods.

Confocal microscopy

Protein expression (CD123 and ABCA1) and phosphorylation (p65, STAT5, and Akt) were evaluated by immunofluorescent staining, as previously described20 (antibodies used appear in supplemental Table 3). Nuclei were labeled with 4’,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) and cholesterol content was investigated using the free cholesterol marker Sima-Aldrich, according to the manufacturer’s recommendations. Relative fluorescence intensity of filipin staining was measured with the ImageJ application, and determined as: corrected total cell fluorescence = [(“integrated density” – “area of selected cell” × “mean fluorescence of background readings”)]/untreated conditions.

Mice and in vivo model

NSG mice were irradiated (2 Gy), inoculated IV 18 hours later with 1 × 106 CAL-1 cells, and treated intraperitoneally 7 days later with 6 injections of T0901317 (total experimental dose, 30 or 60 mg/kg, respectively) or with vehicle control alone, for 24 hours. LXRα isoform and ABCA1 protein expression were evaluated by western blot. The human hepatocellular carcinoma cell line HepG2 was used as control and untreated CAL-1 lysates were used as reference for actin expression. Expression of LXR protein was compared with actin expression with the vehicle condition being considered arbitrary as 1. Results of 1 experiment of 3 are shown. (C) Primary BPDNC cells from 1 patient (LPDC #4) were treated with 1 μM LXR agonists T0901317 (T09) or GW3965 (GW) for 24 hours. Expression of CD123 (as a BPDNC-specific marker) and ABCA1 was assessed by confocal microscopy. Nuclei were stained with DAPI. (D) This cartoon, adapted from Chram and Vaughan,6 represents 1 of the current accepted models of cholesterol efflux, illustrating the cholesterol efflux experiments performed thereafter. Cholesterol is excluded from cells through ABCA1 and/or ABCG1 transporters. Lipid-poor APOA1 accepts cholesterol (yellow symbols) from cells through ABCA1-mediated cholesterol efflux. This induces nascent HDL formation which then accepts supplemental cholesterol loading via ABCG1-mediated efflux. Addition of HDL2 implicates only ABCG1-mediated cholesterol efflux. (E) Cholesterol efflux was assessed using [3H]-cholesterol-acetylated LDL-loaded CAL-1 cells treated with 1 μM T0901317 (T09) or GW3965 (GW) for 24 hours. Cholesterol efflux was triggered by the addition of 20 μg/mL HDL2 (right panel, n = 4) or 10 μg/mL APOA1 (left panel, n = 3). Data were expressed as percentage of cholesterol efflux (mean ± SEM of n experiments), as described in supplemental Methods (*P < .05, Mann-Whitney). (F) Cholesterol content of BPDNC cells was assessed after treatment with T0901317 (T09) or GW3965 (1 μM) for 24 hours followed by a 4-hour incubation with APOA1 cholesterol acceptor (10 μg/mL). Cellular cholesterol content was determined using filipin staining analyzed by confocal microscopy. One representative experiment of 3 for CAL-1 cells, 1 of 2 for GEN2.2 cells, is shown. LDPC represents data of a blood sample from 1 BPDNC patient tested of 4 (LPDC #5, #6, #8, #9). The PDC marker CD123 allows the identification of leukemic PDCs in blood samples. Cumulative filipin fluorescence intensity from the 4 different BPDNC samples was expressed as mean ± SEM (bottom right panel, *P < .05, Mann-Whitney). Fluorescence intensity of the vehicle condition is considered arbitrary as 1.

Results

A BPDNC-specific transcriptomic signature identifies a dysregulation of cholesterol homeostasis

Twelve primary BPDNC samples were analyzed using the Affymetrix U133-2 messenger RNA (mRNA) microarray for the expression of cholesterol homeostasis and LXR-related genes (LXRA, LXRB, ABCA1, ABCG1, APOE, SREBF1, FASN, LDLR, and VLDLR) plus the NFKB1 gene. Comparison with AML and T-ALL samples revealed a specific BPDNC sample clustering, associated with a significant downregulation of LXR target genes ABCA1 and ABCG1 (associated with cholesterol efflux) and an upregulation of the VLDLR gene (linked to cholesterol entry). NFKB1 gene upregulation in BPDNC samples was confirmed (Figure 1B; supplemental Figure 1).22 Comparison of the BPDNC samples with primary PDC samples showed a similar clustering associated with a significant downregulation of LXR target genes, SREBF1 and ABCG1, whereas VLDLR and NFKB1 genes were upregulated (Figure 1C; supplemental Figure 1). This shows that the BPDNC transcriptomic profile is independent of the PDC cell lineage. A significant downregulation of ABCA1 and ABCG1 gene transcription was confirmed by qRT-PCR analysis in 2 BPDNC cell lines (GEN2.2 and CAL-1), BES1 cells, and 4 primary BPDNC samples compared with nonleukemic PDC samples (Figure 1D). Overall, these data identify a specific perturbation of cholesterol homeostasis- and LXR-related gene transcription in BPDNC.

LXR activation stimulates cholesterol efflux from BPDNC

Treatment with 2 synthetic LXR agonists (T0901317 and GW3965, 1 μM, 24 hours) upregulated ABCA1 and ABCG1 gene transcription in CAL-1, GEN2.2 cell lines, and in 4 primary BPDNC samples (Figure 2A). ABCA1 and LXRα proteins were increased after LXR activation in CAL-1 cells, as assessed by western blot analysis (Figure 2B) and in CAL-1 and GEN2.2 cells, as assessed by confocal...
microscopy (supplemental Figure 2). Increase of ABCA1 expression after LXR activation was analyzed in 1 primary BPDCN sample by confocal microscopy (Figure 2C). Because LXR activation induces cholesterol efflux through ABCA1 and ABCG1 in cooperation with cholesterol acceptors, such as APOA1 and HDL2, we then investigated cholesterol efflux using CAL-1 cells preloaded with ³H-cholesterol (1 µCi/mL, 24 hours), and treated with either T0901317 or GW3965 (1 µM, 24 hours) before the addition of APOA1 (10 µg/mL) or HDL2 (20 mg of protein per mL) cholesterol acceptors for 4 hours (Figure 2D). Radioactivity measurement in media and cells demonstrated that LXR agonist treatment significantly increased cholesterol efflux in both conditions (Figure 2E). Intracellular cholesterol staining revealed that LXR agonist treatment followed by APOA1 addition induced a significant diminution of total cholesterol content in CAL-1,
Figure 4. LXR activation in BPDCN cells induces apoptotic cell death. CAL-1, GEN2.2, BES1, and blood samples from 5 patients diagnosed with BPDCN (LPDC #1, #2, #5, #10, #11) were treated with increasing concentrations (10-50 μM) of LXR agonists T0901317 (T09) or GW3965 (GW) for 24 hours. Cell viability was assessed by Annexin V and 7AAD staining and cytometry. (A) Left panel, Dot plots illustrate data obtained with cells treated with 50 μM LXR agonists, except for CAL-1 cells that were treated with **10 μM 50 μM 50 μM 50 μM 50 μM**.
LXR activation inhibits BPDCN cell proliferation and induces apoptotic cell death

Because LXR activation regulates cell proliferation and survival,13,20 we investigated the effects of LXR stimulation on BPDCN cells. CAL-1 cells were treated with increasing concentrations (1 μM, 5 μM, 10 μM) of LXR agonists for 24, 48, or 72 hours. Proliferation analysis of viable cells (AnnexV−/7AAD−) demonstrated a significant decrease of cell proliferation induced by LXR agonist treatment (10 μM, 72 hours, P < .001), as assessed by cytomtery (Figure 3A). Cell cycle phase analysis demonstrated a significant G1 phase retention associated with a diminution of cells in the S phase in a time-dependent (24 or 72 hours) manner (Figure 3B).

Exposure of CAL-1 and GEN2.2 cells to increasing concentrations of LXR agonists (10 μM, 30 μM, or 50 μM) demonstrated a significant cell death induction for concentrations higher than 10 μM, as assessed by AnnexV/7AAD staining and cytometry. The cytotoxic effect of LXR agonists was confirmed in BES1 cells and 5 primary BPDCN samples of 5 tested (P < .05; Figure 4A-B). Assessment of viable BPDCN cells (AnnexV−/7AAD−/CD123+/CD304−) in 1 blood sample from a BPDCN patient revealed after treatment with LXR agonists, a preferential decrease of viable BPDCN cells (77% vs 50% and 30% for vehicle- vs T0901317- and GW3965-treated samples, respectively) (Figure 4B). This suggests a specific cytotoxic effect of LXR agonists on BPDCN cells. Western blot analysis of CAL-1 cells treated with LXR agonists for 6 hours showed a caspase-3 and caspase-9 cleavage, suggesting apoptosis induction (Figure 4C). This was confirmed in CAL-1 and GEN2.2 cells by nucleus fragmentation induced by LXR agonists and at morphological levels, as assessed by confocal microscopy (supplemental Figure 3A-B). Caspase-9 activation was confirmed after LXR agonist treatment in GEN2.2 cells and 2 primary BPDCN cells, as assessed by cytometry (Figure 4D). BAX and BAK1-coding gene upregulation in CAL-1 and GEN2.2 cells after LXR activation was detected (Figure 4E). This suggests the involvement of the intrinsic apoptosis. Overall, this indicated that LXR agonist treatment stimulates apoptotic cell death in BPDCN.

LXR activation interferes with 2 BPDCN survival pathways: the IL-3–induced signaling pathway and NF-κB activation

Because LXR activation inhibits BPDCN survival, we wondered whether LXR stimulation would interfere with the following survival signaling pathways, IL-3 and NF-κB. IL-3 was described to induce STAT5 and Akt activation, both involved in leukemic cell survival.13-16 NF-κB activation was reported to maintain BPDCN cell survival.22 To investigate the effects of LXR activation on IL-3–induced STAT5 and Akt activation, CAL-1 cells were treated with increasing noncytotoxic concentrations of LXR agonists (1–10 μM, 24 hours), followed by IL-3 stimulation (10 ng/mL, 30 minutes). Western blot analysis demonstrated a sustained diminution of STAT5 and Akt phosphorylation induced by LXR agonist treatment (Figure 5A). These effects were confirmed by confocal microscopy in 3 primary BPDCN samples (Figure 5B), as well as in CAL-1 and GEN2.2 cells (supplemental Figure 4A).

To demonstrate the involvement of constitutive NF-κB activation in BPDCN cell survival, CAL-1 and GEN2.2 cells were treated with increasing concentrations (12.5–100 μM, 24 hours) of the NF-κB inhibitor, JSH23. A significant increase of BPDCN cell death was revealed by AnnexV/7AAD staining (***P < .01, Figure 5C). LXR agonists decreased NF-κB p65 phosphorylation in 4 primary BPDCN samples (Figure 5D) and in CAL-1, GEN2.2 cells (supplemental Figure 4B), as assessed by confocal microscopy. Western blot analysis of CAL-1 cells pretreated with LXR agonists (1 μM, 24 hours) demonstrated an inhibition of p50, p65, and c-Rel NF-κB subunit nuclear translocation, induced by a NF-κB activator (R848, 1 μg/mL, 6 hours) (Figure 5E). Overall, these data demonstrated that LXR stimulation in BPDCN cells inhibits IL-3–induced STAT5 and Akt activation, as well as NF-κB activation at phosphorylation and nuclear translocation levels. This may contribute to the cytotoxic effects of LXR agonist treatment on BPDCN.

Stimulation of cholesterol efflux amplifies LXR activation-induced effects

Cholesterol efflux through ABCA1/ABCG1 inhibits IL-3–induced hematopoietic stem cell (HSC) proliferation,13,14 and LXR activation in BPDCN interferes with the IL-3 signaling pathway. To investigate the contribution of LXR-stimulated cholesterol efflux in these effects, CAL-1 and GEN2.2 cells or a primary BPDCN sample were treated with LXR agonists (1 μM, 24 hours), then with APOA1 (10 μg/mL, 4 hours) followed by IL-3 (10 ng/mL, 30 minutes). Addition of APOA1 markedly diminished IL-3–induced STAT5 and Akt phosphorylation in all LXR-treated BPDCN cells (Figure 6A-B). Treatment of CAL-1 cells with increasing noncytotoxic concentrations of LXR agonists (5-10 μM) in the presence of APOA1 (0-20 μg/mL) showed a significant increase of dead BPDCN cells (Figure 6C). Overall, these data demonstrated that cholesterol efflux increases LXR agonist-mediated effects. To go further on cholesterol dependency of BPDCN, cholesterol was deprived from BPDCN cells by using either an inhibitor of the mevalonate pathway, atorvastatin, or a compound inducing cholesterol removal from cells, methyl-β-cyclodextrin.22 Cell death analysis 24 hours later by AnnexV/7AAD staining and cytometry demonstrated a significant BPDCN cell death (supplemental Figure 5).

Figure 4 (continued) 10 μM and 50 μM. Results from 1 representative experiment of 6 for CAL-1, 1 of 4 for GEN2.2 cells, and 1 representative sample (LPDC11) of 5 for primary BPDCN samples tested. Right panel. The percentage of AnnexV− dead cells (mean ± SEM from 6 or 4 independent experiments for CAL-1 and GEN2.2, respectively), after LXR agonist treatment (**P < .05, ***P < .01, ****P < .001, ****P < .0001, Mann-Whitney). (B) One freshly isolated blood sample obtained from a patient diagnosed with BPDCN was treated with 50 μM T0901317 (T09) or GW3965 (GW) for 24 hours. Cytoflorimetry dot plots from 1 representative sample of 5 different BPDCN represent the percentage of BPDCN cells (identified by CD123/BDCA4 staining) in the viable cell fraction of blood sample (ie, the AnnexV−/7AAD− fraction) (**P < 0.05, Mann-Whitney). (C) CAL-1 cells were treated with increasing concentrations of LXR agonists, T0901317 (T09) or GW3965 (GW), for 6 hours. Analysis of full-length inactive (inact.) and cleaved active (act.) forms of caspase-3 and caspase-9 was performed by western blot. Expression of these proteins was compared with actin expression with the vehicle condition being considered as 1. Results from 1 representative experiment of 3. (D) BPDCN cells (GEN2.2 and 2 primary BPDCN samples, LPDC #1 and #5) were treated with 50 μM T0901317 (T09) or GW3965 (GW) for 6 hours. Caspase-9 activation on 7AAD− cell fraction (excluding late apoptotic and necrotic cells) was assessed by cytometry. One dot plot represents 1 representative experiment of 2 for GEN2.2 cells, and the other 2 plots represent the experiments performed on 2 BPDCN samples (LPDC #1 and #5). (E) CAL-1 and GEN2.2 cells were treated with increasing concentrations of LXR agonists (10 μM, 30 μM, and 50 μM) for 6 hours. BCL2, BAX, and BAK1 gene expression was assessed by qRT-PCR. Levels of mRNA were normalized to those of GAPDH for each sample and then expressed as fold change related to the average value for vehicle-treated cells. Cumulative data from 4 independent experiments expressed as mean ± SEM (**P < .05, ***P < .01, Mann-Whitney) are shown. FSC, forward scatter; SSC, side scatter.
Figure 5. LXR activation in BPDCN cells interferes with IL-3–induced STAT5 and Akt phosphorylation, as well as NF-κB activation. (A) CAL-1 cells were treated with increasing concentrations (1 μM, 5 μM, or 10 μM) of LXR agonists (T09 or GW) for 24 hours, followed by 10 ng/mL of IL-3 for 30 minutes. Phospho-STAT5 (Y694), phospho-Akt (S473), as well as unphosphorylated corresponding protein expression was assessed by western blot. The expression of these proteins was compared with actin with the vehicle condition being considered as 1. Results of 1 representative experiment of 2. (B) BPDCN cells (LPDC #5) were treated with 1 μM LXR agonists for 24 hours. Phospho-STAT5 (Y694) and phospho-Akt (S473) were assessed by confocal microscopy after IL-3 stimulation (10 ng/mL, 30 minutes). Results of 1 representative sample (LPDC #5) of
In vivo LXR agonist treatment prevents cytopenia and BPDCN cell infiltration

To assess LXR therapeutic effects in vivo, sublethally irradiated (2 Gy) NSG mice were grafted with 1 million CAL-1 cells. After 7 days, mice were treated with 2 doses of LXR agonist (T0901317 30 mg/kg or 60 mg/kg) or vehicle, every 2 days until sacrifice. Although CAL-1 cell injection induced a significant persistent decrease of red blood cell (RBC), platelet counts, as well as hemoglobin (Hb) concentration, T0901317-treated mice showed a significant prevention of cytopenia, including RBC counts and Hb concentration (Figure 7A). At sacrifice, a diminution of CAL-1 cell-induced splenomegaly was observed (Figure 7B), supported by a potent decrease of spleen and bone marrow BPDCN cell infiltration, as assessed by flow cytometry (Figure 7C). In an additional experiment, treatment with T0901317 (30 mg/kg or 60 mg/kg) significantly increased the overall survival of NSG mice inoculated with CAL-1 cells compared with CAL-1-inoculated and vehicle-treated mice (Figure 7D-E). Overall, these data provide the in vitro and in vivo demonstration of a therapeutic effect of LXR agonist on BPDCN through different mechanisms, including signaling pathway regulation and cholesterol efflux.

Discussion

Cholesterol is a critical component for cell growth and proliferation, as illustrated by the inhibition of HSC proliferation occurring after cholesterol efflux through ABC transporters. In physiological conditions, cholesterol homeostasis is tightly controlled by the LXR signaling pathway. Here, we identified that the aggressive hematological malignancy BPDCN exhibits a specific transcriptional signature with a downregulation of several LXR target genes involved in cholesterol homeostasis. This may lead to cholesterol accumulation within leukemic cells, responsible for high proliferative properties. We reported that LXR agonist treatment increases LXR target gene expression in BPDCN, stimulates cholesterol efflux from these cells, and is associated with the inhibition of proliferation and survival. These 2 effects may result from the interference of LXR activation with 2 BPDCN survival/proliferative pathways, namely IL-3 and NF-κB signaling pathways. The effects of LXR agonists are amplified by the addition of the lipid acceptor APOA1 known to enhance cholesterol efflux. All of these effects (except cell proliferation) were assessed in vitro in 2 BPDCN cell lines, expanded primary BPDCN cells, and several primary BPDCN samples isolated from 11 different patients. An in vivo therapeutic effect of LXR agonist is also observed in a xenograft model with reduction of BPDCN cell infiltration, prevention of BPDCN-induced cytopenia, and increased mouse survival. These data highlight an unrevealed perturbation of cholesterol homeostasis and LXR activity in BPDCN, and identify a new approach based on LXR agonists to treat this aggressive hematological malignancy.

Treatment of BPDCN with LXR agonists has several effects depending on their concentration. Restoration of LXR target gene expression (inducing cholesterol efflux) and inhibition of IL-3 and NF-κB signaling pathways occurred for concentrations between 1 and 10 μM (ranges usually used in malignant cells). BPDCN cell proliferation (assessed with the proliferative BPDCN cell line, CAL-1) was significantly inhibited for 10 μM, as reported in several hematological malignancies and solid tumors. Concentrations higher than 10 μM induced a significant BPDCN cell death, as reported for ovarian, breast, and colon cancer cells. All of these data validate the concentrations of LXR agonists used in this study.

LXR activation in BPDCN triggers an apoptotic cell death mechanism based on different features, namely: exposure of phosphatidylserine (assessed by AnxV staining), cleavage of caspase-3 and caspase-9, as well as nucleus fragmentation. Induction of intrinsic apoptosis by LXR agonists was previously described in ovarian carcinoma cells, and confirmed here associated with a significant increase of BAX and BAK1 transcripts (encoding proapoptotic proteins). LXR-induced cell death in breast cancer cells has been demonstrated to implicate BAX upregulation and to be dependent on cholesterol efflux through ABCG1. In our study, a stimulation of ABCA1/ABCG1-dependent cholesterol efflux via the addition of APOA1 increases LXR-mediated cytotoxic effects. APOA1-stimulated cholesterol efflux also potentiates the LXR-induced inhibition of Akt and STAT5 phosphorylation. This is in line with a previous report in prostate cancer cells showing Akt inhibition by increased cholesterol efflux. Although exogenous APOA1 supplementation is required for in vitro assays with BPDCN cells, circulating lipid-free APOA1 (mainly produced by liver and intestine), or APOA1 present in nascent HDL is likely to potentiate the impact of LXR agonist treatment in vivo. Overall, LXR stimulation in BPDCN exerts an antileukemic effect that can be enhanced by increasing cholesterol efflux.

Therapeutic strategies of BPDCN propose to interfere with IL-3, NF-κB signaling pathways, because BPDCNs express high levels of CD123, and IL-3 is a BPDCN survival factor. Here, we explored how LXR activation and induced cholesterol efflux interact with this pathway. No modification of CD131 and CD123 expression on BPDCN cells after LXR activation is observed (data not shown), whereas LXR agonists inhibit IL-3–induced Akt and STAT5 phosphorylation in BPDCN. Western blot analysis demonstrated that LXR agonists had no effect on STAT5 and Akt protein expression, suggesting a predominant effect at the phosphorylation levels.

BPDCN samples exhibit a specific downregulation of LXR target genes ABCG1, ABCA1, and SREBF1, in favor of repression of LXR transcriptional activity. However, although LXR target gene transcription is decreased in BPDCN, the transcripts of the 2 LXR coding genes (LXRα and LXRβ) are not and basal LXRβ protein (supplemental Figure 2B) is present. This suggests posttranscriptional regulation of LXR activity in BPDCN. LXR activity in normal PDC is inhibited by prior NF-κB activation. Because NF-κB is constitutively activated in BPDCN, and NF-κB p105 precursor-coding gene (NFKB1) is upregulated, LXR repression in BPDCN may be related to NF-κB activation. Restoration of the LXR pathway by agonist treatment in BPDCN inhibits the constitutive NF-κB activation at 3 different levels.
Figure 6. Cholesterol efflux stimulation in BPDCN cells amplifies LXR activation-induced effects. BPDCN CAL-1 and GEN2.2 cells or primary BPDCN samples were treated with 1 µM LXR agonists T0901317 (T09) or GW3965 (GW) for 24 hours. (A-B) Phospho-STAT5 (Y694) and phospho-Akt (S473) were assessed by confocal microscopy after LXR stimulation, followed by APOA1 (10 µg/mL) addition for 4 hours, and then IL-3 stimulation (10 ng/mL for 30 minutes). (A) Data from 1 representative sample of 2 BPDCN samples (LPDC #5, #8) are shown. (B) Data from 1 representative experiment of 3 for CAL-1 and GEN2.2 cells are shown. (C) CAL-1 cells were treated with 10 µM T0901317 or GW3965 simultaneously to increasing concentrations of APOA1 (5, 10, or 20 µg/mL) for 24 hours. Cell death was assessed by AnxV/7AAD staining analyzed by cytometry. Dot plots from 1 representative experiment of 6 are shown (left panel); only data obtained with GW treatment are depicted. Cumulative data from the 6 independent experiments expressed as mean ± SEM of dead AnxV⁺ cells are shown (right panel, *P < .05, **P < .01, Mann-Whitney).
In vivo LXR agonist treatment limits BPDCN-induced cytopenia, spleen and bone marrow infiltration by BPDCN, and also improves overall mouse survival.

NSG mice were sublethally irradiated (2 Gy), and then injected IV with $1 \times 10^7$ CAL-1 cells. After 7 days, mice were treated with 2 doses of the LXR agonist T0901317 (30 mg/kg or 60 mg/kg) or with vehicle control (PBS/DMSO 50%) every 2 days, until the end of the experiments (4 mice per group, 3 independent experiments).

(A) Blood samples were collected every 4 days to assess RBC and Hb concentration. Cumulative data expressed as mean ± SEM of CAL-1 cell infiltration percentage from 5 mice. (B) At the end of the experiments ($\pm 2$), spleens were extracted and measured to evaluate BPDCN spleen involvement. (C) Spleens and bone marrow were collected in order to perform CAL-1 cell quantification. Cells were stained with the following antibodies: human CD45 (hCD45), murine CD45 (mCD45), CD123, and BDCA4 and analyzed by cytometry. Dot plots illustrate the gating strategy with identification of murine cells using mCD45 staining with irradiated mice used as control. Human CAL-1 cells were identified using hCD45, CD123, and BDCA4 staining. Cultured CAL-1 cells were used as control for this staining. Percentage of cell infiltration was calculated as follows: CAL-1 count/(hCD45 + mCD45 counts). Histograms represent cumulative data of 1 experiment of 3 expressed as mean ± SEM of CAL-1 cell infiltration percentage from 5 mice. (D) Overall survival of BPDCN-inoculated mice treated with LXR agonist T0901317 (30 mg/kg, pink triangles; 60 mg/kg, red triangles) or with vehicle (black squares). Irradiated mice (gray circles) were used as control. Statistical comparisons were performed between vehicle and treated groups using the Mantel-Cox test ($^{*}P < .05$, $^{**}P < .01$). (E) Mean overall survival of BPDCN-inoculated mice treated with LXR agonist or vehicle. Bars correspond to the mean of survival time ($^{*}P < .05$, Mann-Whitney). Results from 1 additional experiment with 5 mice per group are shown.
p65 phosphorylation, nuclear translocation of the p50, p65, and cRel subunits, as well as transcription of NFκB1 (data not shown). Our study confirms constitutive NF-κB activation in BPDCN cells,32 and demonstrates that inhibition of p65 translocation by JSH-23 is sufficient to induce BPDCN cell death. This suggests that LXR agonist-induced cell death is related to NF-κB inhibition. Interestingly, STAT5 and NF-κB were also reported to promote G1 to S cell cycle phase transition through cyclin D1 induction, and thus cell proliferation.47,48 In our study, BPDCN cells are retained in G1 phase after LXR activation. This suggests that LXR-induced STAT5 and NF-κB inhibition can be involved in both the inhibition of cell proliferation (through cell cycle arrest) and BPDCN cell death.

LXR agonist treatment of mice grafted with BPDCN cells prevents leukemia-induced cytopenia, reduces BPDCN spleen and bone marrow infiltrations, and slightly but significantly improves mouse survival. To date, the development of LXR agonists in clinical settings has been hampered by unwanted systemic side effects, such as fatty liver disease and LDL elevation.19 Synthetic LXR agonists have been shown to exert therapeutic effects in mouse models of Alzheimer disease after oral administration.13 This suggests that these agonists can cross the blood-brain barrier and may target BPDCN cells infiltrating the CNS. The CNS may represent a blast cell sanctuary in BPDCN patients with leukemic presentation both at diagnosis and at relapse.4 Efforts are currently being made to generate new synthetic agonists with increased specificity for the LXRβ isof orm, expressed by BPDCNs, to limit steatosis19,49 and/or to stimulate LXR specificity in a target tissue.50,51 Our study supports a new approach for BPDCN treatment using these new synthetic LXR agonists.

Acknowledgments

The authors thank T. Maeda (Nagasaki University, Japan) for kindly providing the BPDCN cell line CAL-1. J. Plumas and L. Chaperot for kindly providing the BPDCN cell line GEN2.2, W. Le Goff (INSERM UMR S1166, University “Pierre et Marie Curie”, Paris, France) for helpful discussions on cholesterol metabolism, the Cytology laboratory of the Etablissement Français du Sang Bourgogne Franche-Comté (BFC), for blood cell and platelet counts, Sarah Oudrin, and Alexis Varin for editorial assistance.

This work was supported by the Etablissement Français du Sang (grant 2011-11) (P.S.), the Agence Nationale de la Recherche (LabEx LipSTIC, ANR-11-LABX-0021), the Conseil Régional de Franche-Comté (soutien au LabEx LipSTIC 2015 and 2016) (P.S.), and the Fondation de Coopération Scientifique Bourgogne Franche-Comté (A.C., D.M., and P.S. via the Bonus Qualité Recherche BFC).

There are no current or pending patents related to this work. Two material transfer agreements related to the use of CAL-1 cell line and the GEN2.2 cell line are available.

Authorship

Contribution: A.C. performed most of the experiments, collected, assembled, and analyzed data, performed statistical analysis, and wrote the manuscript; D.M. performed cholesterol efflux experiments and helped to write the manuscript; A.R. and C.R. performed transcriptomic experiments and analysis; C.C. performed cell death analysis by flow cytometry, some immunoblotting, and qRT-PCR experiments; T.G. performed some confocal microscopy experiments; L.P. performed cell cycle experiments; B.L., F.A.-D., and F.B. performed and supported in vivo experiments; S.P. commented on the manuscript and helped to write it; S.B., C.P., and E.M. provided leukemia samples and diagnosis; L.L. commented on the manuscript and provided major funding support; F.G.-O. provided study material, collected data, and helped to write the manuscript; and P.S. supervised research, analyzed data, and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for B.L. is Université Pierre et Marie Curie, UMR 938, INSERM, Paris, France.

ORCID iD: Philippe Saas, 0000-0002-8857-9939.

Correspondence: Philippe Saas, EFS BFC, UMR 1098, INSERM, 8 rue JFX Girod, BP1937, F-25020 Besançon Cedex, France; e-mail: philippe.saas@efs.sante.fr.

References


LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

Adam Ceroi, David Masson, Anne Roggy, Christophe Roumier, Cécile Chagué, Thierry Gauthier, Laure Philippe, Baptiste Lamarthée, Fanny Angelot-Delettre, Francis Bonnefoy, Sylvain Perruche, Sabeha Biichle, Claude Preudhomme, Elisabeth Macintyre, Laurent Lagrost, Francine Garnache-Ottou and Philippe Saas